Innovative Diagnostic Portfolio Rosetta Genomics offers a diverse range of proprietary microRNA-based tests including thyroid and cancer origin classifiers, supported by core molecular testing capabilities. This positions the company as a strong partner for advanced molecular diagnostics and personalized medicine solutions in oncology and pathology markets.

Recent Market Expansion The company's launch of OncoGxOne, a comprehensive NGS panel, demonstrates a commitment to integrating next-generation sequencing into clinical diagnostics. This opens opportunities for collaboration with healthcare providers seeking cutting-edge genetic testing services to enhance diagnostic accuracy.

Strategic Acquisition Opportunity Having been acquired by Genoptix for $10 million in late 2017, Rosetta presents potential for strategic partnerships or integrations within the oncology diagnostics space, especially with labs or companies aiming to expand their molecular testing offerings.

Target Market & Partnerships With testing services available in CAP-accredited and CLIA-certified labs and collaborations across oncology, endocrinology, and urology, there are opportunities to expand service distribution, especially with providers seeking high-quality, accredited molecular diagnostics.

Growth & Revenue Potential Generating between $10 million and $25 million in revenue with a moderate-sized team, Rosetta is positioned as an agile company poised for growth. Partnering to co-develop new tests or expanding existing platforms can unlock additional revenue streams and market share.